Context Therapeutics Inc Stock Price, News & Analysis

Context Therapeutics (NASDAQ:CNTX) will present two poster presentations at the Society for Immunotherapy of Cancer 40th Annual Meeting, November 7–9, 2025, in National Harbor, MD.

One poster is a Trial in Progress for the Phase 1, first‑in‑human study of CT-95 (mesothelin x CD3 TCE) in advanced solid tumors (Abstract #586), scheduled Saturday, November 8, 2025 at 10:00 AM ET in Prince George ABC Exhibit Halls. The second poster covers preclinical efficacy, safety, and PK data for CT-202 (Nectin-4 x CD3 TCE) (Abstract #963), scheduled Friday, November 7, 2025 at 10:00 AM ET in Prince George ABC Exhibit Halls.

Abstracts are available via the SITC 40th Annual Meeting website.

Context Therapeutics (Nasdaq: CNTX) granted a non-qualified stock option inducement to a new employee on October 1, 2025 under Nasdaq Listing Rule 5635(c)(4). The award covers 30,000 shares with an exercise price of $0.97 per share (Nasdaq closing price on the grant date). Options have a 10‑year term and vest over 4 years: 25% on the first anniversary and the remaining 75% in 36 equal monthly installments, subject to continued service. The grant was made outside the company’s 2021 Long‑Term Performance Incentive Plan as permitted by Nasdaq rule as an inducement for employment.

Context Therapeutics (Nasdaq: CNTX), a clinical-stage biopharmaceutical company focused on developing T cell engaging bispecific antibodies for solid tumors, has announced its participation in two upcoming investor conferences.

The company will present at the Cantor Global Healthcare Conference 2025 on September 3 with a fireside chat at 10:55 AM ET, and at the H.C. Wainwright 27th Annual Global Investment Conference on September 8 with a fireside chat at 3:30 PM ET. Both events will be held in New York, NY and include one-on-one meeting opportunities with management.

Context Therapeutics (Nasdaq: CNTX), a clinical-stage biopharmaceutical company, reported Q2 2025 financial results and pipeline updates. The company maintains a strong financial position with $83.5 million in cash, expected to fund operations into 2027. Context is advancing two key clinical programs: CTIM-76 (CLDN6 x CD3 bispecific antibody) and CT-95 (MSLN x CD3 bispecific antibody), with initial data expected in 2026.

The company reported a net loss of $8.8 million for Q2 2025, with R&D expenses increasing to $7.8 million compared to $1.4 million in Q2 2024. Notable developments include the first patient dosed in the CT-95 Phase 1 trial and the appointment of Dr. Karen Chagin as Chief Medical Officer.

Context Therapeutics (NASDAQ: CNTX) announced a Trial in Progress poster presentation at the 2025 ASCO Annual Meeting for their Phase 1 clinical trial of CTIM-76, a Claudin 6 x CD3 T cell engager bispecific antibody. The trial, which began in January 2025, is evaluating CTIM-76's safety and efficacy in patients with CLDN6-positive advanced or metastatic ovarian, endometrial, and testicular cancers. Currently in cohort 3 with 7 active trial sites across the United States, the study aims to enroll up to 70 patients. The trial will assess safety, tolerability, pharmacokinetics, and anti-tumor activity metrics including overall response rate, duration of response, and disease control rate. Initial data from the trial is expected to be shared in the first half of 2026.

Context Therapeutics (NASDAQ: CNTX) has appointed Dr. Karen Chagin as Chief Medical Officer, effective June 9, 2025. Dr. Chagin brings significant expertise in T cell therapy development, having previously served as Senior Vice President at Adaptimmune where she contributed to the approval of Tecelra®, the first engineered cell therapy approved for solid tumors in the U.S. She also held the CMO position at Tmunity before its acquisition by Kite Pharma.

Dr. Chagin succeeds interim CMO Dr. Karen Smith, who will remain on the Company's Board. As part of her employment agreement, Dr. Chagin will receive an inducement grant of 153,000 stock options, vesting over four years, with an exercise price set at the closing price on her employment start date.

Context Therapeutics (Nasdaq: CNTX), a clinical-stage biopharmaceutical company focused on T cell engaging bispecific antibodies for solid tumors, has granted inducement stock options to two new employees. The grants total 160,000 shares of common stock, awarded outside the company's 2021 Long-Term Performance Incentive Plan. The options were granted on May 5 and May 12, 2025, with exercise prices of $0.839 and $0.78 per share respectively. These 10-year options vest over four years, with 25% vesting after the first year and the remainder vesting monthly over the following three years, contingent on continued employment.

Context Therapeutics (CNTX) reported Q1 2025 financial results and business updates. The company has $89.4 million in cash, expected to fund operations into 2027. Two product candidates are in Phase 1 clinical trials: CTIM-76 (Claudin 6 x CD3 bispecific antibody) and CT-95 (mesothelin x CD3 bispecific antibody). Initial clinical data is expected in H1 2026 for CTIM-76 and mid-2026 for CT-95. The company reported a net loss of $4.6 million for Q1 2025, compared to $3.7 million in Q1 2024. R&D expenses increased to $3.5 million from $2.0 million year-over-year. Context plans to file an IND for CT-202, a Nectin-4 x CD3 bispecific antibody, in mid-2026.

Context Therapeutics (NASDAQ: CNTX) announced a leadership transition as Dr. Karen Smith takes over as interim Chief Medical Officer (CMO), replacing Dr. Claudio Dansky Ullmann who will depart on May 10, 2025. Dr. Smith, currently a Board member, will serve in a dual capacity while the company searches for a permanent CMO.

Dr. Smith brings over 20 years of experience in drug development and commercialization, having previously served as Global Head of R&D and CMO at Jazz Pharmaceuticals, with additional senior leadership roles at Allergan, AstraZeneca, and Bristol Myers Squibb. She will oversee the company's clinical development programs during this transition period.